The HITSLEVIK peptide corresponding to PF4 in patients with early-stage CRC (2.65-fold, p < 0.0001) and late-stage CRC (2.90-fold, p < 0.0001) was significantly higher than that of the HC group (Figure 2A). The gene discussed is PF4; the disease is colorectal carcinoma.